- €897.31m
- €513.16m
- €535.18m
Brief: Curevac Receives Additional Positive Validity Decision From European Patent Office In Ongoing Litigation Against Biontech SE
Brief: Curevac Q4 Pre-Tax Loss At EUR 38.6 Mln
CureVac rises on COVID vaccine patent decision
European Patent Office declares CureVac mRNA patent valid
Brief: Curevac Receives Positive Validity Decision From European Patent Office In Litigation Against Biontech SE
Vaccine makers gain amid growing concerns around bird flu
Vaccine makers gain amid growing concerns around bird flu
Brief: Curevac Says Corporate Redesign On Track with 30% Workforce Reduction, Posts Q3 Results
Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents (updated)
Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents
Brief: CureVac Second Quarter Revenues Amounted To 14.4 Mln Euros
Factbox: European companies cut jobs as economy sputters
Factbox: European companies cut jobs as economy sputters
Brief: German Cartel Office: GSK Cleared To Buy Curevac Assets
Factbox: European companies cut jobs as economy sputters
Press Digest: British Business - July 4
CureVac soars on COVID, influenza vaccines deal with GSK
London stocks rebound on gains in metal miners ahead of elections
UK Stocks-Factors to watch on July 3 (updated)